Drug Trial Radar · NCT06380881
PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
May 20, 2024
Primary completion
Aug 6, 2025
Study completion Aug 6, 2025
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection in the treatment of skeletal-related event and cancer pain.
Conditions
- Patients With Bone Metastases
Interventions
SHR-2017Drug
SHR-2017
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Pharmacokinetic parameters of SHR-2017 after administration, including CmaxTime frame: First dose up to 169 days post-dose
- The Pharmacokinetic parameters of SHR-2017 after administration, including TmaxTime frame: First dose up to 169 days post-dose
- The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-tTime frame: First dose up to 169 days post-dose
- The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-∞Time frame: First dose up to 169 days post-dose
- The Pharmacokinetic parameters of SHR-2017 after administration, including t1/2Time frame: First dose up to 169 days post-dose
- The Pharmacokinetic parameters of SHR-2017 after administration, including CL/FTime frame: First dose up to 169 days post-dose
- The pharmacodynamic parameter of SHR-2017 after administration include uNTX/uCrTime frame: First dose up to 169 days post-dose
- The pharmacodynamic parameter of SHR-2017 after administration include β-CTXTime frame: First dose up to 169 days post-dose
- The pharmacodynamic parameter of SHR-2017 after administration include BALP [TimeTime frame: First dose up to 169 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.